Who is sponsoring NCT05911503?

NCT05911503 is sponsored by Tianjin Medical University.

What drugs are being tested in NCT05911503?

Interventions in NCT05911503: 2% Ganciclovir Eye Drops.

What condition does NCT05911503 study?

NCT05911503 studies Cytomegalovirus Retinitis, Ganciclovir Eye Drops.

Is NCT05911503 still recruiting?

NCT05911503 is currently recruiting now. Last updated 23 June 2023.

Last reviewed 2023-06-23 · How we verify

NCT05911503

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis

Recruiting now EARLY_PHASE1 Last updated 23 June 2023

What this trial tests

EARLY_PHASE1 trial testing 2% Ganciclovir Eye Drops in Cytomegalovirus Retinitis in 15 participants. Currently enrolling.

Timeline

1 July 2023

Primary endpoint
1 June 2027

30 June 2027

Quick facts

Lead sponsor	Tianjin Medical University
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	1 July 2023
Primary completion	1 June 2027
Estimated completion	30 June 2027
Sites	1 location across China

Drugs / interventions tested

2% Ganciclovir Eye Drops — full drug profile →

Conditions studied

Cytomegalovirus Retinitis — all drugs for Cytomegalovirus Retinitis →
Ganciclovir Eye Drops — all drugs for Ganciclovir Eye Drops →

Sponsor

Tianjin Medical University

Who can join

Adults 2 to 80, any sex, with Cytomegalovirus Retinitis or Ganciclovir Eye Drops. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Clinical study of high concentration ganciclovir eye drops in the treatment of cytomegalovirus retinitis

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Tianjin Medical University trials

Trials by the same sponsor.

NCT07393685 — Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD · not yet recruiting
NCT07306598 — [18F]NIDF PET Imaging in Tau-related Diseases · recruiting
NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
NCT06949670 — Alpha-Synuclein PET/CT in Various α-Syn-Related Disease · recruiting
NCT06628531 — ALI & Pulmonary HA Deposition After SAH · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05911503 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University
Last refreshed: 23 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05911503.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing